P. Cheema

1.1k total citations
22 papers, 842 citations indexed

About

P. Cheema is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, P. Cheema has authored 22 papers receiving a total of 842 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Genetics. Recurrent topics in P. Cheema's work include Chronic Lymphocytic Leukemia Research (7 papers), Cancer Treatment and Pharmacology (5 papers) and Lymphoma Diagnosis and Treatment (4 papers). P. Cheema is often cited by papers focused on Chronic Lymphocytic Leukemia Research (7 papers), Cancer Treatment and Pharmacology (5 papers) and Lymphoma Diagnosis and Treatment (4 papers). P. Cheema collaborates with scholars based in United States, Canada and Peru. P. Cheema's co-authors include Rakesh K. Chandra, R. K. Chandra, Nicholas Mitsiades, Renate Burger, Teru Hideshima, Paul G. Richardson, Nikhil C. Munshi, Dharminder Chauhan, Kenneth C. Anderson and Reshma Shringarpure and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

P. Cheema

22 papers receiving 808 citations

Peers

Countries citing papers authored by P. Cheema

Since Specialization

Citations

This map shows the geographic impact of P. Cheema's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Cheema with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Cheema more than expected).

Fields of papers citing papers by P. Cheema

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Cheema. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Cheema. The network helps show where P. Cheema may publish in the future.

Co-authorship network of co-authors of P. Cheema

This figure shows the co-authorship network connecting the top 25 collaborators of P. Cheema. A scholar is included among the top collaborators of P. Cheema based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Cheema. P. Cheema is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CYP2D6 activity in patients with metastatic breast cancer treated with single agent tamoxifen: results from ECOG-ACRIN E3108 2024 ·Breast Cancer Research and Treatment ·Vered Stearns, Anne O’Neill, Bryan P. Schneider, Todd C. Skaar, Minetta C. Liu, Caroline Lohrisch, Matthew P. Goetz, Carlos Vallejos, Joseph A. Sparano, Diego Villa, Paula Silverman, P. Cheema, Dennis F. Moore, George W. Sledge	1
2	SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers. 2023 ·Journal of Clinical Oncology ·Rachna T. Shroff, Katherine A. Guthrie, Aaron J. Scott, Mitesh J. Borad, Laura W. Goff, Khalid Matin, Amit Mahipal, Aparna Kalyan, Milind Javle, Carol Aghajanian, Benjamin Tan, P. Cheema, Anuj Patel, Renuka Iyer, Robin Kate Kelley, Jaykumar Thumar, Anthony B. El-Khoueiry, E. Gabriela Chiorean, Howard S. Höchster, Philip Agop Philip	57
3	A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408 2020 ·Clinical Cancer Research ·Andrew M. Evens, Fangxin Hong, Thomas M. Habermann, Ranjana H. Advani, Randy D. Gascoyne, Thomas E. Witzig, Andrew Quon, Erik A. Ranheim, Stephen M. Ansell, P. Cheema, (unknown), Timothy E. O’Brien, Jane N. Winter, Terrence P. Cescon, Julie Chang, Brad S. Kahl	16
4	Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study 2020 ·Blood ·Giselle K. Perez, Fangxin Hong, Andrew M. Evens, Thomas M. Habermann, Ranjana H. Advani, Stephen M. Ansell, P. Cheema, (unknown), Timothy E. O’Brien, Jane N. Winter, Julie Chang, David Cella, Brad S. Kahl, Lynne I. Wagner	1
5	Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Results of the E2905 Intergroup Phase III Study - an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health 2019 ·Blood ·Alan F. List, Zhuoxin Sun, Amit Verma, John M. Bennett, (unknown), Jaroslaw P. Maciejewski, Rami S. Komrokji, Timothy R. Wassenaar, Selina M. Luger, Ryan J. Mattison, P. Cheema, Jessica K. Altman, David F. Claxton, Charles A. Schiffer, Andrew Artz, Mark R. Litzow, Martin S. Tallman	3
6	Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis 2019 ·Annals of Oncology ·Sendhilnathan Ramalingam, (unknown), Yuichiro Ohe, Byoung Chul Cho, Johan Vansteenkiste, C. Zhou, Thanyanan Reungwetwattana, Ying Cheng, (unknown), Riyaz Shah, (unknown), P. Cheema, (unknown), Thomas John, Meng‐Chih Lin, Fumio Imamura, Rachel Hodge, Yuri Rukazenkov, Jean‐Charles Soria, David Planchard	49
7	Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102 2018 ·Journal of Clinical Oncology ·Noah Kornblum, Fengmin Zhao, Judith Manola, Paula Klein, Bhuvaneswari Ramaswamy, Adam Brufsky, Phillip J. Stella, Brian L. Burnette, Melinda L. Telli, Della Makower, P. Cheema, Cristina I. Truica, Antonio C. Wolff, Gamini S. Soori, Barbara Haley, Timothy R. Wassenaar, Lori J. Goldstein, Kathy D. Miller, Joseph A. Sparano	141
8	A 3-Arm Randomized Phase II Trial with Bendamustine/Rituximab Therapy in Untreated High Risk (HR) Follicular Lymphoma (FL): Bortezomib Induction or Novel IMiD® Continuation (BIONIC) Study from the ECOG-ACRIN Cancer Research Group 2017 ·Blood ·Andrew M. Evens, Fangxin Hong, Thomas M. Habermann, Ranjana H. Advani, Randy D. Gascoyne, Thomas E. Witzig, Andrew Quon, Erik A. Ranheim, P. Cheema, (unknown), Timothy E. O’Brien, Jane N. Winter, Terrence P. Cescon, Julie Chang, Brad S. Kahl	4
9	P2.07-029 CheckMate 169: Safety/Efficacy of Nivolumab in Canadian Pretreated Advanced NSCLC (including Elderly and PS 2) Patients 2017 ·Journal of Thoracic Oncology ·Rosalyn A. Juergens, Quincy S. Chu, J. Rothenstein, F. De Angelis, Shantanu Banerji, (unknown), (unknown), Paul Bégin, (unknown), (unknown), (unknown), Ji Young Yun, (unknown), (unknown), (unknown), P. Cheema	12
10	Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG‐ACRIN Cancer Research Group (E4203) 2017 ·Cancer ·Neal J. Meropol, Yang Feng, Jean L. Grem, Mary F. Mulcahy, Paul J. Catalano, John Kauh, Michael J. Hall, Joel Saltzman, Thomas J. George, Jeffrey Zangmeister, E. Gabriela Chiorean, P. Cheema, Peter J. O’Dwyer, Al B. Benson	6
11	Combined Treatment with Lenalidomide (LEN) and Epoetin Alfa (EA) Is Superior to Lenalidomide Alone in Patients with Erythropoietin (Epo)-Refractory, Lower Risk (LR) Non-Deletion 5q [Del(5q)] Myelodysplastic Syndrome (MDS): Results of the E2905 Intergroup Study-an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health 2016 ·Blood ·Alan F. List, Zhuoxin Sun, Amit Verma, John M. Bennett, Kathy L. McGraw, Lisa Nardelli, Jaroslaw P. Maciejewski, Jessica K. Altman, P. Cheema, David F. Claxton, Rami S. Komrokji, Selina M. Luger, Ryan J. Mattison, (unknown), Andrew Artz, Charles A. Schiffer, Martin S. Tallman	12
12	A phase II prospective trial correlating progression-free survival (PFS) with CYP2D6 activity in patients with metastatic breast cancer treated with tamoxifen: ECOG-ACRIN E3108. 2016 ·Journal of Clinical Oncology ·Vered Stearns, Anne O’Neill, Bryan P. Schneider, David A. Flockhart, Todd C. Skaar, Minetta C. Liu, Caroline Lohrisch, Matthew P. Goetz, (unknown), Joseph A. Sparano, Diego Villa, Paula Silverman, P. Cheema, Dennis F. Moore, George W. Sledge	1
13	Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): A randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408). 2016 ·Journal of Clinical Oncology ·Andrew M. Evens, Fangxin Hong, Thomas M. Habermann, Ranjana H. Advani, Randy D. Gascoyne, Thomas E. Witzig, Andrew Quon, Lynne I. Wagner, Stephen M. Ansell, Adam M. Petrich, Julie Chang, Timothy E. O’Brien, P. Cheema, Terrence P. Cescon, Keren Sturtz, Brad S. Kahl	5
14	Prediction and early detection of anthracycline-related cardiotoxicity using cardiac biomarkers. 2014 ·Journal of Clinical Oncology ·(unknown), Daniel J. Lenihan, Bonnie Ky, Carla L. Warneke, (unknown), Vandana G. Abramson, Ingrid A. Mayer, Paul T. Adams, (unknown), P. Cheema, Dennis F. Moore, (unknown), Joseph R. Carver, Michael Fisch	4
15	Clinical risk prediction in anthracycline cardiotoxicity. 2014 ·Journal of Clinical Oncology ·Bonnie Ky, Carla L. Warneke, Daniel J. Lenihan, P. Cheema, Dennis F. Moore, (unknown), (unknown), Paul T. Adams, (unknown), Joseph R. Carver, Sunita D. Nasta, Jakub Svoboda, Stephen J. Schuster, Nishitha Reddy, (unknown), Alyssa G. Rieber, Marcella M. Johnson, Michael Fisch	1
16	Panitumumab Monotherapy in Patients with Metastatic Colorectal Cancer and Cetuximab Infusion Reactions: A Series of Four Case Reports 2009 ·Clinical Colorectal Cancer ·(unknown), (unknown), Edith P. Mitchell, P. Cheema, Mona Shing	24
17	Institutional experiences with panitumumab monotherapy in metastatic colorectal cancer (mCRC) patients (pts) intolerant to cetuximab 2007 ·Journal of Clinical Oncology ·(unknown), Edith P. Mitchell, P. Cheema, (unknown), Mona Shing	7
18	Thalidomide analogue IMiD3 provides T cell co-stimulation through B7-CD28 pathway. 2002 ·Blood ·Richard LeBlanc, Teru Hideshima, Tateki Hayashi, (unknown), Renate Burger, Reshma Shringarpure, P. Cheema, Paul G. Richardson, KC Anderson, (unknown)	1
19	Influence of maternal food antigen avoidance during pregnancy and lactation on incidence of atopic eczema in infants 1986 ·Clinical & Experimental Allergy ·R. K. Chandra, (unknown), (unknown), P. Cheema	124
20	Predictive value of cord blood IgE in the development of atopic disease and role of breast‐feeding in its prevention 1985 ·Clinical & Experimental Allergy ·Rakesh K. Chandra, (unknown), P. Cheema	103

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact